Article Text

PDF
Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase γ (POLG1)
  1. R McFarland1,2,
  2. G Hudson2,
  3. R W Taylor2,
  4. S H Green3,
  5. S Hodges1,
  6. P J McKiernan3,
  7. P F Chinnery1,2,
  8. V Ramesh1
  1. 1
    Newcastle upon Tyne NHS Hospitals Trust, Newcastle upon Tyne, UK
  2. 2
    Newcastle University, Newcastle upon Tyne, UK
  3. 3
    Birmingham Children’s Hospital, Birmingham, UK
  1. Dr Robert McFarland, Mitochondrial Research Group, School of Neurology, Neurobiology and Psychiatry, 4th Floor, The Medical School, Framlington Place, Newcastle University, Newcastle NE2 4HH, UK; robert.mcfarland{at}ncl.ac.uk

Abstract

We report the case of a 2-year-old boy with seizures who developed hepatic failure shortly after commencing sodium valproate. Unexpectedly, liver function returned to normal on stopping the drug. Sequencing of the mitochondrial polymerase γ gene (POLG1) revealed four heterozygous substitutions, two of which have been identified in cases of Alpers-Huttenlocher disease.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.